WO2017180108A1 - Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé - Google Patents

Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé Download PDF

Info

Publication number
WO2017180108A1
WO2017180108A1 PCT/US2016/027108 US2016027108W WO2017180108A1 WO 2017180108 A1 WO2017180108 A1 WO 2017180108A1 US 2016027108 W US2016027108 W US 2016027108W WO 2017180108 A1 WO2017180108 A1 WO 2017180108A1
Authority
WO
WIPO (PCT)
Prior art keywords
level
cholesterol
bodily fluid
sample
lipoid
Prior art date
Application number
PCT/US2016/027108
Other languages
English (en)
Inventor
Randice Lisa Altschul
Neil David THEISE
Myron Rapkin
Rebecca O'brien
Original Assignee
Pop Test LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pop Test LLC filed Critical Pop Test LLC
Priority to EP16898797.2A priority Critical patent/EP3455627A4/fr
Priority to PCT/US2016/027108 priority patent/WO2017180108A1/fr
Publication of WO2017180108A1 publication Critical patent/WO2017180108A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521—Single-layer analytical elements
    • G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Definitions

  • the present invention relates generally to devices and formulations for reagents employed in such devices that enable detecting, screening and monitoring levels of certain constituents in bodily fluids sampled from humans and animals, and pertains, more specifically, to the construction and manufacture of such devices.
  • the present invention provides formulations and devices that enable a user to employ a bodily fluid, such as saliva or another oral fluid, serum or plasma, utilizing devices that provide color changes to indicate the presence and level of a certain constituent in the bodily fluid. Further, the present invention provides methods of construction and manufacture that enable such devices to be made available for widespread use for detecting, screening or monitoring the presence and level of any one of a plurality of certain constituents with increased ease and economy.
  • a bodily fluid such as saliva or another oral fluid, serum or plasma
  • the present invention attains several objects and advantages, some of which are summarized as follows: Provides devices of simplified construction for widespread use in detecting, screening and monitoring the presence and level of any selected one of a plurality of certain constituents in bodily fluids; enables an exceptionally rapid response in a quick and easy non-invasive procedure for determining the presence and level of a particular constituent in a bodily fluid; provides for the economical manufacture and distribution of devices capable of detecting, screening and monitoring the presence of certain constituents in bodily fluids; makes available a simplified visual reading of a color change to determine the presence and level of a certain constituent in a bodily fluid; provides an economical and reliable device for simplified use in detecting, screening or monitoring the presence of a selected certain constituent in a bodily fluid; encourages widespread use to the benefit of a larger number of users who can enjoy greater economy and convenience in reaching and maintaining higher goals in healthcare.
  • the present invention may be described briefly as a method of making a device for conducting a non-invasive analysis of a bodily fluid to determine the presence and the level of a certain constituent carried by the bodily fluid, the device including an indicator formulation capable of changing color in response to exposure to the certain constituent to provide a visible indication of the presence and the level of the certain constituent carried by the bodily fluid, the method comprising: providing a carrier substrate of a material having voids establishing a high void volume within the carrier substrate; applying a chromagen formulation to the carrier substrate to create a chromagen-laden carrier member; and subsequently applying to the chromagen- laden carrier member a selected reagent having a particular constituent-specific formulation to combine the selected reagent with the chromagen formulation applied to the carrier substrate, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid later placed upon the carrier substrate; wherein the different certain constituents are alanine aminotransferase
  • the present invention provides a device for conducting a non-invasive analysis of a bodily fluid to determine the presence and the level of a certain constituent carried by the bodily fluid, the device including an indicator formulation capable of changing color in response to exposure to the certain constituent to provide a visible indication of the presence and the level of the certain constituent carried by the bodily fluid, the device comprising: a carrier substrate of a material having voids establishing a high void volume within the carrier substrate; and an indicator formulation carried by the carrier substrate, the indicator formulation consisting essentially of a chromagen formulation and a constituent-specific formulation selected from formulations responsive to levels of either one of the certain constituents alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
  • ALT alanine aminotransferase
  • AST aspartate aminotransferase
  • the present invention also provides a device for conducting a non-invasive analysis of a bodily fluid to determine the presence and the level of a selected one of the low density and high density lipoid fractions of cholesterol carried by the bodily fluid, the device including an indicator formulation capable of changing color in response to exposure to cholesterol to provide a visible indication of the presence and the level of cholesterol carried by the bodily fluid, the device comprising: at least first and second test pads, each test pad being comprised of a carrier substrate of a material having voids establishing a high void volume within the carrier substrate; an indicator formulation carried by the carrier substrate of each test pad, the indicator formulation consisting essentially of a chromagen formulation and a cholesterol-specific formulation responsive to the presence and level of cholesterol; a treatment pad j uxtaposed with the second test pad; and a lipoid precipitation agent carried by the treatment pad, the lipoid precipitation agent being specific to the precipitation of one of the low density and high density lipoid fractions of cholesterol such that upon applying a sample of
  • the present invention provides a method for conducting a non-invasive analysis of a bodily fluid to determine the presence and the level of a selected one of the low density and high density lipoid fractions of cholesterol carried by the bodily fluid, the method including the provision of an indicator formulation capable of changing color in response to exposure to cholesterol to provide a visible indication of the presence and the level of cholesterol carried by the bodily fluid, the method comprising: providing at least first and second test pads, each test pad being comprised of a carrier substrate of a material having voids establishing a high void volume within the carrier substrate; including the indicator formulation in the carrier substrate of each test pad, the indicator formulation consisting essentially of a chromagen formulation and a cholesterol-specific formulation responsive to the presence and level of cholesterol; applying a sample of the bodily fluid to the first test pad; juxtaposing a treatment pad with the second test pad; providing a lipoid precipitation agent carried by the treatment pad, the lipoid precipitation agent being specific to the precipitation of one of the low density and high density lip
  • the present invention provides a method of screening for non-alcoholic fatty liver disease (NAFLD) in a patient, said method comprising the steps of: (a) obtaining a biological sample from a patient; (b) providing a plurality of detector devices, wherein each detector device comprises at least one detection reagent which specifically binds to an analyte, wherein the detection reagent specifically binds an analyte selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), wherein the binding of detection reagent to analyte provides a visual indication of the presence and level of analyte in the sample, (c) applying the sample to the at least one detector device, and (d) ascertaining the presence and level of said analyte in said sample.
  • NAFLD non-alcoholic fatty liver disease
  • the present invention provides a method of screening for non-alcoholic fatty liver disease (NAFLD) in a patient, said method comprising the steps of: (a) obtaining a biological sample from a patient; (b) providing a detector device, wherein the detector device comprises a plurality of detection reagents which specifically binds to an analyte selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and combinations thereof, wherein the binding of detection reagent to analyte provides a visual indication of the presence and level of analyte in the sample, (c) applying the sample to the detector device, and (d) ascertaining the presence and level of analyte in said sample.
  • NAFLD non-alcoholic fatty liver disease
  • the present invention provides a method of screening for liver cancer in a patient, said method comprising the steps of: (a) obtaining a biological sample from a patient; (b) providing a plurality of detector devices, wherein each detector device comprises at least one detection reagent which specifically binds to an analyte selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), wherein the binding of detection reagent to analyte provides a visual indication of the presence and level of analyte in the sample, (c) applying the sample to the at least one detector device, and (d) ascertaining the presence and level of said analyte in said sample.
  • each detector device comprises at least one detection reagent which specifically binds to an analyte selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), wherein the binding of detection rea
  • the present invention provides a method of screening for liver cancer in a patient, said method comprising the steps of: (a) obtaining a biological sample from a patient; (b) providing a detector device, wherein the detector device comprises a plurality of detection reagents which specifically binds to an analyte, selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and combinations thereof, wherein the binding of detection reagent 6 027108
  • to analyte provides a visual indication of the presence and level of analyte in the sample, (c) applying the sample to the detector device, and (d) ascertaining the presence and level of analyte in said sample.
  • the present invention provides a method of screening for level of low density lipoid fractions of cholesterol in a patient, said method comprising the steps of: (a) obtaining a biological sample from a patient; (b) providing a device for conducting a noninvasive analysis of a bodily fluid to determine the presence and the level of low density lipoid factions of cholesterol carried by the bodily fluid, the device including an indicator formulation capable of changing color in response to exposure to cholesterol to provide a visible indication of the presence and the level of cholesterol carried by the bodily fluid, the device comprising: at least first and second test pads, each test pad being comprised of a carrier substrate of a material having voids establishing a high void volume within the carrier substrate; an indicator formulation carried by the carrier substrate of each test pad, the indicator formulation consisting essentially of a chromagen formulation and a cholesterol- specific formulation responsive to the presence and level of cholesterol; a treatment pad juxtaposed with the second test pad; and a lipoid precipitation agent carried by the treatment pad, the lipo
  • the present invention provides A method of screening the presence and the level of low density lipoid fractions of cholesterol in a patient, said method comprising the steps of: (a) obtaining a biological sample from a patient; (b) providing a device for conducting a non-invasive analysis of a bodily fluid to determine the presence and the level of low density lipoid fractions of cholesterol carried by the bodily fluid, the device including an indicator formulation capable of changing color in response to exposure to cholesterol to provide a visible indication of the presence and the level of cholesterol carried by the bodily fluid, the device comprising: at least first and second test pads, each test pad being comprised of a carrier substrate of a material having voids establishing a high void volume within the carrier substrate; an indicator formulation carried by the carrier substrate of each test pad, the indicator formulation consisting essentially of a chromagen formulation and a cholesterol-specific formulation responsive to the presence and level of cholesterol; a treatment pad juxtaposed with the second test pad; and a lipoid precipitation agent carried by the treatment pad, the
  • the terms “subject” and “patient” are used interchangeably.
  • the term “patient” refers to an animal, preferably a mammal such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., monkey and human), and most preferably a human.
  • the subject is a non-human animal such as a farm animal (e.g., a horse, pig, or cow) or a pet (e.g., a dog or cat).
  • the subject is an elderly human.
  • the subject is a human adult.
  • the subject is a human child.
  • the subject is a human infant.
  • predetermined reference range refers to a reference range for the particular patient, subject, or a population of subjects. Each laboratory may establish its own reference range for each particular assay, or a standard reference range for each assay may be made available and used locally, regionally, nationally, or worldwide or may be patient-specific. In one specific embodiment, the term refers to a reference range for the amount of e.g., glucose, cholesterol, alanine aminotransferase (ALT), and/ or aspartate aminotransferase (AST) in a patient or a specimen from a patient.
  • ALT alanine aminotransferase
  • AST aspartate aminotransferase
  • the term refers to a reference range for the amount of e.g., glucose, cholesterol, alanine aminotransferase (ALT), and/or aspartate aminotransferase (AST) in a patient or a specimen from a patient.
  • the assay may be run simultaneously with a second control assay wherein the control sample does not contain elevated levels of analyte.
  • the assay may be run simultaneously with a control set of analyte standards to generate a standard curve from which sample presence and levels of analyte can be quantitated.
  • FIG. 1 is a pictorial view of a device constructed in accordance with the present invention
  • FIG.2 is an enlarged, somewhat diagrammatic, cross-sectional view taken along line 2-2 of FIG. 1;
  • FIG. 3 is a flow diagram illustrating a method of the present invention
  • FIG. 4 is a plan view of another device constructed in accordance with the present invention.
  • FIG. 5 is a pictorial view showing use of the device of FIG. 4;
  • FIG. 6 is a pictorial view showing the use of still another device constructed in accordance with the present invention.
  • FIG. 7 is a pictorial view showing the use of yet another device constructed in accordance with the present invention.
  • FIG. 8 is a fragmentary pictorial view of another device constructed in accordance with the present invention.
  • FIG. 9 is an enlarged fragmentary cross-sectional view taken along line 9-9 of FIG. 8;
  • FIG. 10 is a fragmentary pictorial view of yet another device constructed in accordance with the present invention.
  • FIG. 11 is a partially diagrammatic and enlarged fragmentary cross-sectional view taken along line 1 1-1 1 of FIG. 10.
  • a device constructed in accordance with the present invention is shown in the form of a dry-reagent device 20 and is seen to include a carrier substrate in the form of a pad 22 of a material having voids 24 establishing a high void volume within the pad 22.
  • An indicator formulation is carried by the pad 22 and is illustrated at 30 in the form of a layer 32 carried by fibers 34 of the material, in juxtaposition with voids 24 within the pad 22.
  • Indicator formulation 30 consists essentially of a chromagen formulation and a reagent having a constituent-specific formulation selected from formulations responsive to one of a plurality of constituents, as will be set forth in greater detail below.
  • the reagent having a constituent-specific formulation and the chromagen formulation are combined within the pad 22 such that the indicator formulation 30 is capable of changing color in response to exposure to the certain constituent to provide a visible indication on the pad 22 of the presence and the level of the certain constituent carried by a sample of a bodily fluid applied to the pad 22.
  • the occurrence of a visible color change will provide at least a qualitative indication of the presence of the particular specific constituent to which the constituent-specific formulation will react. An absence of any visible color change will indicate that the specific constituent is not present in any significant amount in the saliva sample.
  • the preferred material for pad 22 is a non-woven fibrous material which provides the requisite high void volume.
  • the high void volume provides pad 22 with the ability to absorb rapidly the sample of bodily fluid applied to the target area 36, to enable rapid interaction of the sample with the indicator formulation 30, and to maximize exposure of the interacting sample and indicator formulation to ambient air for promoting a quick response through accelerating a reaction between the certain constituent carried by the sample and the indicator formulation.
  • Non-woven synthetic polymeric materials are available commercially, one such material being a non-woven polyester fibrous material. Suitable glass-fiber non-woven fibrous materials and cellulose non- woven fibrous materials also are available commercially in forms suitable for use in the construction of pad 22.
  • the preferred materials are chosen to provide pad 22 with a void volume within a range of about eight to twelve percent of the total volume of the material.
  • Device 20 is constructed in several different variations such that one variation is available to provide a visible color change as an indication of at least the presence of a corresponding one of several certain constituents, namely, ethanol, uric acid, galactose, glucose, cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and, preferably, the level of the certain constituent, in the sample of bodily fluid applied to the target area 36 of the pad 22.
  • Each variation requires that the pad 22 carry a formulation specific to the constituent to be detected, as a component of the indicator formulation 30; however, the chromagen formulation remains unchanged among the different variations of the pad 22 so that the same chromagen formulation can serve in every variation of the pad 22. Accordingly, the manufacture and distribution of the devices 20 is simplified and rendered more economical, as will be described below.
  • pad 22 of device 20 is manufactured by first applying to the material of pad 22 the chromagen formulation, as seen in step 40, to create a chromagen-laden carrier member in the form of pad 22 with the chromagen formulation placed in juxtaposition with voids 24 of the pad 22. Subsequently, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden carrier member, as indicated at step 42, to combine the selected reagent with the chromagen formulation applied earlier to the material of pad 22, thereby establishing the indicator formulation 30 within the completed pad 22. Pad 22 is placed at target area 36 of device 20 for reception of the sample of bodily fluid upon the pad 22.
  • chromagen formulation remains the same for all variations of the device 20
  • economies are realized in the manufacturing process which requires only one component common to all variations and only one station for the application of that common component; however, further economy and convenience are accomplished by the ability to store the intermediate product, that is, the material of pad 22 with the applied chromagen formulation, is stored, as seen in step 44.
  • any selected one of the constituent- specific formulations is applied, at a later time, in accordance with the requirement for any number of a particular device or particular devices, the completed carrier member with the indicator formulation being available at step 46.
  • a preferred common chromagen formulation consists essentially of the following components, in an example prepared as follows: Approximately equal volumes of about 0.05 to 0.5 M MBTH in distilled water is mixed with about 0.05 to 0.5 M DMAB in ethanol. An alternate formulation consists essentially of approximately 500 to 1,000 mg DAOS mixed with 100 ml ethanol. The mixture is impregnated into the material of the carrier member and the impregnated material subsequently is dried, leaving the material with the chromagen formulation coated upon the fibers of the material.
  • Other chromagen formulations compatible with the present reactions will become apparent to those persons of ordinary skill in the art.
  • a constituent-specific formulation consists essentially of the following components, in an example prepared as follows: Mix together approximately equal amounts of about 1% to 20% PVP K30 in distilled water, about 0.5% to 5% ethoxylated surfactant in distilled water and about 0.05 to 0.5 M phosphate buffer at pH 8.5 together with one-half the same amount of alcohol oxidase with an activity of approximately 400 U/ml and one- quarter the same amount of peroxidase with an activity of approximately 200 U/mg. The prepared constituent-specific formulation then is impregnated into the material previously impregnated with the chromagen formulation to complete a pad 22 having an indicator formulation 30 responsive to the presence and level of ethanol in an applied sample of a bodily fluid.
  • a constituent-specific formulation consists essentially of the following components, in an example prepared as follows: In approximately one-hundred ml of 0.05 to 0.5 M phosphate buffered saline at pH 6.4, mix together approximately ten mg of uricase, fifteen mg of ascorbate oxidase and about six mg of peroxidase with an activity of approximately 200 U/mg. The prepared constituent-specific formulation then is impregnated into the material previously impregnated with the chromagen formulation to complete a pad 22 having an indicator formulation 30 responsive to the presence and level of uric acid in an applied sample of a bodily fluid.
  • a constituent-specific formulation consists essentially of the following components, in an example prepared as follows: Mix together approximately five ml each of about 0.05 to 0.5 M phosphate buffer at pH 7.0, peroxidase with an activity of about 200 U/mg, and ethanol (95%) together with about twenty-five ml of 10% polyvinyl alcohol in distilled water and 4200 units of galactose oxidase. The prepared constituent-specific formulation then is impregnated into the material previously impregnated with the chromagen formulation to complete a pad 22 having an indicator formulation 30 responsive to the presence and level of galactose in an applied sample of a bodily fluid.
  • a constituent-specific formulation consists essentially of the following components, in an example prepared as follows: Dissolve approximately equal amounts of the enzymes glucose oxidase with an activity of approximately 200 U/mg and peroxidase with an activity of approximately 200 U/mg in distilled water in the presence of approximately equal amounts of 0.05 to 0.5 M HEPES, a blend of surface active agents within the range of about 0.1% to 10% each, and a stabilizer, the preferred stabilizer being a PVP/copolymer complex in which the copolymer is methyl vinylether/maleic anhydride, available commercially under the trademark GANTREZ® , the complex being prepared from 5% PVP K30 in distilled water and 5% GANTREZ® AN 139 at a pH of about 7.5.
  • the prepared constituent-specific formulation then is impregnated into the material previously impregnated with the chromagen formulation to complete a pad 22 having an indicator 7108
  • formulation 30 responsive to the presence and level of glucose in an applied sample of a bodily fluid.
  • a constituent-specific formulation consists essentially of the following components, mixed together in the indicated proportions: About 100 mg of L-alanine, about 2200 units of pyruvate oxidase, about 560 mg of 4- aminoantipyrine, about 10,000 units of peroxidase, about 12,000 units of ascorbate oxidase, about 400 mg of thiamine pyrophosphate, about 640 mg of magnesium chloride and about lOOuL of 10% ON870, all mixed with about 100 ml of distilled water.
  • a constituent-specific formulation consists essentially of the following components, mixed together in the indicated proportions: About 200 mg of sodium-L-aspartate, about 16 mg of a-ketoglutaric acid, about 1060 mg of oxalacetic acid decarboxylase, about 2200 units of pyruvate oxidase, about 640 mg of 4- aminoantipyrine, about 10,000 units of peroxidase, about 12,000 units of ascorbate oxidase, about 3.8 mg of thiamine pyrophosphate, about 6.4 mg of magnesium chloride and about lOOuL of 10% ON870, all mixed with about 100 ml of distilled water.
  • a constituent-specific formulation consists essentially of the following components, in an example prepared as follows: Dissolve approximately equal amounts of the enzymes cholesterol esterase with an activity of approximately 180U/mg and peroxidase with an activity of approximately 200 U/mg and twice as much cholesterol oxidase with an activity of approximately 47 U/mg) in distilled water in the presence of approximately equal amounts of 0.05 to 0.5 M HEPES, a blend of surface active agents within the range of about 0.1% to 10% each and a stabilizer, the preferred stabilizer being a PVP/copolymer complex in which the copolymer is methylvinylether/maleic anhydride, available commercially under the trademark GANTREZ®, the complex being prepared from 5% PVP K30 in distilled water and 5% GANTREZ® AN 139 at a pH of about 7.5.
  • the prepared constituent-specific formulation then is impregnated into the material previously impregnated with the
  • the present invention provides the ability to employ dry reagent techniques, as disclosed above, lateral flow techniques, as disclosed in United States Patent No. 8,889,427, or a combination of both techniques to achieve that end.
  • a dry-reagent device 220 that includes a target area 236 having adjacent independent sections 240 and 242 placed for reception of a sample of bodily fluid, such as a saliva sample.
  • Section 240 includes a test pad 244 constructed as described above in connection with pad 22 and carrying the constituent-specific formulation for the detection of the presence and level of cholesterol.
  • a second test pad 246 is located remote from first test pad 244 and also is constructed as described above in connection with pad 22, carrying the constituent-specific formulation for detecting cholesterol.
  • Section 242 includes a treatment pad 250 that carries a lipoid precipitation agent, such as an organic acid, specific to the precipitation of the LDL fraction of cholesterol.
  • a lipoid precipitation agent such as an organic acid
  • Section 242 includes a treatment pad 250 that carries a lipoid precipitation agent, such as an organic acid, specific to the precipitation of the LDL fraction of cholesterol.
  • a portion of the sample upon introducing a sample of bodily fluid, such as a saliva sample, to the target area 236, a portion of the sample will enter test pad 244 and a color change indicative of the total level of cholesterol present in the sample portion will appear at a surface 256 of test pad 244, while another portion of the sample will enter treatment pad 250, will pass through treatment pad 250, and will enter test pad 246, so that a color change indicative of the level of the HDL fraction of cholesterol present in the sample portion will appear at a surface 2 8 of the test pad 246, the LDL fraction having been removed at the treatment pad 250.
  • the level of the LDL fraction can be determined directly by removing the HDL fraction with an appropriate lipoid precipitation agent in the treatment pad 250 so that the color change at test pad 246 will be indicative of the level of the LDL fraction of cholesterol present in the sample portion.
  • VLDL very low density lipoids
  • Device 320 includes a test strip 322 having a target area 324 placed for reception of a sample of bodily fluid, such as a saliva sample.
  • Test strip 322 is constructed of a porous material that enables removal of a first portion of the sample laterally, as illustrated diagrammatically at 326 in FIG. 11, to a first test pad 330 which carries a constituent-specific formulation for the detection of the presence and level of cholesterol.
  • a second portion of the sample is moved laterally, as illustrated diagrammatically at 336, toward a second test pad 340 placed adjacent first test pad 330, the second test pad 340 being isolated from first test pad 330 by a barrier 342.
  • Test pad 340 likewise carries the constituent-specific formulation for detecting cholesterol.
  • a treatment pad 350 is interposed between the target area 324 and the second test pad 340, in position to receive the second portion of the sample from the target area 324.
  • Treatment pad 350 carries a lipoid precipitation agent, such as an organic acid, specific to the precipitation of the LDL fraction of cholesterol.
  • a filter member 354 that precludes passage of the liquid precipitation agent from treatment pad 350 into test pad 340.
  • a sample of bodily fluid such as a saliva sample
  • a color change at test pad 330 indicative of the total level of cholesterol present in the sample will be read at 360, while a color change indicative of the level of the HDL fraction remaining after removal of the LDL fraction at treatment pad 350 will be read at 362.
  • the levels of total cholesterol and of the HDL fraction then are used in connection with a standard algorithm to calculate, at 364, the level of the LDL fraction present in the bodily fluid, which level is displayed at 366.
  • the level of the LDL fraction can be determined directly by removing the HDL fraction with an appropriate lipoid precipitation agent in the treatment pad 350 so that the color change at test pad 340 will be indicative of the level of the LDL fraction of cholesterol present in the sample portion.
  • test pads 244 and 246, as well as test pads 330 and 340 can be in parallel, or in series, or in any feasible relationship adjacent to one another enabling the flow of sample material into corresponding test pads.
  • the test pads can be on the same or on opposite sides of a test strip. Any reading of the results of a test can be made from the top side or from the bottom side of the test strip, or from both sides.
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • a patient having signs of elevated levels of cholesterol AND elevated levels of glucose, accompanied by elevated levels of ALT AND elevated levels of AST the patient is very likely to have NAFLD or NASH.
  • a patient having signs of elevated levels of cholesterol OR elevated levels of glucose, accompanied by elevated levels of ALT AND elevated levels of AST is likely to have NAFLD or NASH.
  • a patient having signs of elevated levels of cholesterol AND elevated levels of glucose, accompanied by elevated levels of ALT OR elevated levels of AST the patient is likely to have NAFLD or NASH.
  • a biological sample can be a member selected from the group consisting of whole blood, serum, plasma, cerebrospinal fluid, saliva, urine, spinal fluid, synovial fluid, amniotic fluid and cranial fluid, and lymphocyte or cell culture supernatants.
  • the detection reagent can be selected from the group consisting of chromagens; antigens; haptens; monoclonal and polyclonal antibodies; natural and synthetic mono-, oligo- and polysaccharides; lectins; avidin and streptavidin; biotin; growth factors; hormones; receptor molecules; and combinations thereof.
  • NAFLD can cause primary liver cancer, in particular hepatocellular carcinoma (HCC), so reliable screening protocols for the presence of NAFLD become of even greater importance for determining populations requiring more aggressive screening for liver cancer.
  • HCC hepatocellular carcinoma
  • a notoriously chemo-resistant tumor it is likely that further new treatments will be necessitated by such an explosion in NAFLD- associated malignancies.
  • glucocorticoid-receptor often is expressed in the nuclei of HCC, indicating that the tumor is likely responsive to the chemo-sensitizing effects of Org34517, as has already been demonstrated in xenograft models of human, GR-expressing ovarian and breast carcinomas, as set forth in United States Patent No. 8,658,128.
  • a disk-shaped device 100 includes a pad 110 constructed of the material previously described in connection with pad 22 of device 20.
  • Pad 110 provides a target area 112 which, in device 110, is substantially surrounded by an integrated color gauge 114 having patches 116 of different colors that can be matched visually with a color change at the target area 112.
  • device 100 provides a simple semi- qualitative/semi-quantitative measure of the presence and level of a particular certain constituent carried by a sample of bodily fluid applied to the target area 112.
  • the semi- qualitative/semi-quantitative indication while more comprehensive than the generally qualitative indication provided by device 20 described above, is convenient, as shown in FIG. 5 where the device 100 is placed readily within the palm 118 of a user's hand, but not as comprehensive as the indication provided by other embodiments of the invention, as set forth below.
  • a device 120 is constructed as described in detail in the aforesaid patents, Nos. 7,824,344 and 7,993,283, and is inserted into a reader 122 that employs an algorithm which converts a sensed color change into an accurate digital readout at a display 124, for a more accurate quantitative evaluation of the presence and level of a particular certain constituent carried by a bodily fluid sample.
  • a device 130 carries a strip 132 similar in construction to pad 22 described above, and arranged in a coil 134 held within the device 130.
  • a sample of bodily fluid is applied to the strip 132, at a target area registered with an access door 140 through which the sample is passed to the strip 132.
  • a color change is sensed and an algorithm converts the sensed color change into an accurate digital readout at a display 142.
  • the used portion 144 of the strip 132 is advanced through a slot 146 and is torn off and discarded.
  • FIGS. 6 and 7 are conveniently available to a user wishing to control and maintain weight levels.
  • the algorithms provided by these embodiments can convert the detected glucose level into glycemic control readily understood and employed by a user in connection with a weight control regimen.
  • the user is provided with information to refine glycemic control, enabling the user to adjust diet, supplement intake and exercise for the purpose of glycemic control and weight control.
  • a dry-reagent device, a lateral flow device, or another test device preferably constructed in the form of a dipstick
  • a kit suitable for home testing is incorporated into a kit suitable for home testing.
  • a screening test as described above, would provide convenience, privacy and eliminate the necessity and cost of visiting a physician for a screening test, although the dipstick or other test device-based kit could also be used in a clinical setting.
  • the dipstick or other test device-based kit would be similar to a home pregnancy kit, known to those of skill in the art, and could provide a color indication of, or an increased risk for, e.g., NAFLD/NASH and the like described herein, e.g., an analyte such as glucose, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
  • an analyte such as glucose, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
  • Such a test device-based kit could be provided with a small plastic cup for collecting and retaining the sample and for conducting the test.
  • the dipstick or other test device could react to produce one color if a level of a first analyte, a different color if a level of, e.g., a second analyte is exceeded, and when both levels are exceeded, the two colors would combine to yield a third color easily distinguishable from the others.
  • the present invention attains all of the objects and advantages summarized above, namely: Provides devices of simplified construction for widespread use in detecting, screening and monitoring the presence and level of any selected one of a plurality of certain constituents in bodily fluids; enables an exceptionally rapid response in a quick and easy non-invasive procedure for determining the presence and level of a particular constituent in a bodily fluid; provides for the economical manufacture and distribution of devices capable of detecting, screening and monitoring the presence of certain constituents in bodily fluids; makes available a simplified visual reading of a color change to determine the presence and level of a certain constituent in a bodily fluid; provides an economical and reliable device for simplified use in detecting, screening or monitoring the presence of a selected certain constituent in a bodily fluid; encourages widespread use to the benefit of a larger number of users who can enjoy greater economy and convenience in reaching and maintaining higher goals in healthcare.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un dispositif permettant d'effectuer une analyse non invasive d'un fluide corporel en vue de déterminer la présence et le niveau d'un certain constituant porté par le fluide corporel. Une formulation d'indicateur du dispositif change de couleur en réponse à une exposition au constituant en vue de fournir une indication visible de la présence et du niveau du constituant porté par le fluide corporel. Un substrat de support du dispositif est constitué d'un matériau présentant des vides fournissant un volume de vide élevé à l'intérieur du substrat. Le dispositif est fabriqué par application d'un chromogène sur le substrat de support en vue de créer un élément de support chargé en chromogène. Ensuite, un réactif sélectionné présentant une formulation spécifique à un constituant particulier est appliqué sur l'élément chargé en chromogène. Le réactif sélectionné se combine alors au chromogène, établissant ainsi la formulation d'indicateur à l'intérieur du substrat de support en place permettant la réception d'un échantillon du fluide corporel.
PCT/US2016/027108 2016-04-12 2016-04-12 Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé WO2017180108A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16898797.2A EP3455627A4 (fr) 2016-04-12 2016-04-12 Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé
PCT/US2016/027108 WO2017180108A1 (fr) 2016-04-12 2016-04-12 Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/027108 WO2017180108A1 (fr) 2016-04-12 2016-04-12 Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé

Publications (1)

Publication Number Publication Date
WO2017180108A1 true WO2017180108A1 (fr) 2017-10-19

Family

ID=60042690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/027108 WO2017180108A1 (fr) 2016-04-12 2016-04-12 Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé

Country Status (2)

Country Link
EP (1) EP3455627A4 (fr)
WO (1) WO2017180108A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1155944A1 (en) * 1981-08-03 1985-05-15 Ki Nii Endokrinologii Method of manufacturing indicating strips for determining glucose in blood
US5580744A (en) * 1992-04-27 1996-12-03 Avocet Medical, Inc. Test article and method for performing blood coagulation assays
US20020086435A1 (en) * 2000-12-28 2002-07-04 Fernandez Decastro Aurora L. Test strip for simultaneous detection of a plurality of analytes
WO2005031351A1 (fr) * 2003-09-23 2005-04-07 Oakville Hong Kong Co., Limited Dispositifs de dosage a flux lateral et procedes d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9366674B2 (en) * 2010-10-23 2016-06-14 Pop Test LLC Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1155944A1 (en) * 1981-08-03 1985-05-15 Ki Nii Endokrinologii Method of manufacturing indicating strips for determining glucose in blood
US5580744A (en) * 1992-04-27 1996-12-03 Avocet Medical, Inc. Test article and method for performing blood coagulation assays
US20020086435A1 (en) * 2000-12-28 2002-07-04 Fernandez Decastro Aurora L. Test strip for simultaneous detection of a plurality of analytes
WO2005031351A1 (fr) * 2003-09-23 2005-04-07 Oakville Hong Kong Co., Limited Dispositifs de dosage a flux lateral et procedes d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GURYANOVA L. N. ET AL.: "Diagnosticheskoe znachenie laboratornykh metodov issledovaniya", THE DIAGNOSTIC VALUE OF LABORATORY RESEARCH METHODS LEARNING TOOLKIT = ДИАГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ ЛАБОРАТОРНЫХ МЕТОДОВ ИССЛЕДОВАНИЯ УЧЕБНО МЕТОДИЧЕСКОЕ ПОСОБИЕ, 2008, Saransk, pages 39 , 41, 57, 58, XP009513125 *
PAVLOV CH. S. ET AL.: "Nealkogolnaya zhirovaya bolezn pecheni v klinike vnutrennikh organov", RMZH 2010, pages 1742, XP055566972 *
See also references of EP3455627A4 *

Also Published As

Publication number Publication date
EP3455627A1 (fr) 2019-03-20
EP3455627A4 (fr) 2020-10-21

Similar Documents

Publication Publication Date Title
de Campos et al. Alternative matrices in forensic toxicology: A critical review
EP4293357A2 (fr) Dispositif et méthodes
CN105738635A (zh) 一种分级快速半定量测试早早孕胶体金试纸、试剂盒及检测方法
CN102135498A (zh) 一种以多捕获特性为特征的半定量胶体金属检测技术及其制备方法和用途
CN1318849C (zh) 以颜色为基础的生化和免疫分析中的光谱测量
AU2022201958A1 (en) Diagnostic testing for immunologic food sensitivity
US9366674B2 (en) Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method
US10160994B2 (en) Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method
US8263345B2 (en) Method for preparing standardized serum mixture for determining allergen potency and the use thereof
US7867720B2 (en) Food sensitivity testing in animals
WO2017180108A1 (fr) Dispositifs et formulations permettant de détecter, sélectionner et surveiller des niveaux de certains constituants dans des fluides corporels, et procédé
US20020013002A1 (en) Pregnancy test based on saliva or other bodily fluids
WO1997037035A1 (fr) Analyse de l'antigene specifique de la prostate dans un extrait de sang entier sur un support solide
CA2814350C (fr) Dispositifs et formulations pour detecter, selectionner et controler des niveaux de certains constituants dans liquides organiques, et procede
WO2010104646A1 (fr) Procédé de test pour diagnostiquer l'hypertension chez un patient et procédé de traitement et kit de test associés
US20230404546A1 (en) Bodily fluid indicator devices and methods
Dhakshinya et al. Use of Urinary Reagent Strips in Testing Cerebrospinal Fluid For Meningitis-A Review.
Tomasik et al. Fast diagnostics of urinary tract infections in children using dipsticks.
JP2024059028A (ja) 検査キット及び検査方法
CN108459166A (zh) 一种同时检测喹诺酮类抗生素残留量的方法
Cowden Alpha-amylase as a putative biomarker of academic stress in undergraduate students
Bonnand et al. Evaluation of psychotrope use from urine samples in subjects attending a drug abuse clinic for the first time
JPH1123572A (ja) 生理状態の評価方法および簡易生理状態評価キット
CN101082628A (zh) 以颜色为基础的生化和免疫分析中的光谱测量

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016898797

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016898797

Country of ref document: EP

Effective date: 20181112

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16898797

Country of ref document: EP

Kind code of ref document: A1